Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Cash from Investing Activities (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Cash from Investing Activities for 9 consecutive years, with -$27.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 1062.8% year-over-year to -$27.0 million, compared with a TTM value of -$36.2 million through Dec 2025, down 77.06%, and an annual FY2025 reading of -$36.2 million, down 77.06% over the prior year.
  • Cash from Investing Activities was -$27.0 million for Q4 2025 at Puma Biotechnology, down from $506000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $11.2 million in Q3 2023 and bottomed at -$27.0 million in Q4 2025.
  • Average Cash from Investing Activities over 5 years is -$4.0 million, with a median of -$3.4 million recorded in 2021.
  • The sharpest move saw Cash from Investing Activities soared 278.93% in 2022, then plummeted 1700.0% in 2025.
  • Year by year, Cash from Investing Activities stood at $4.6 million in 2021, then plummeted by 356.94% to -$11.9 million in 2022, then skyrocketed by 31.19% to -$8.2 million in 2023, then skyrocketed by 71.6% to -$2.3 million in 2024, then plummeted by 1062.8% to -$27.0 million in 2025.
  • Business Quant data shows Cash from Investing Activities for PBYI at -$27.0 million in Q4 2025, $506000.0 in Q3 2025, and -$11.2 million in Q2 2025.